{"nct_id":"NCT06627647","title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC","status":"RECRUITING","status_verified_date":"2025-09","start_date":"2024-11-27","start_date_type":"ACTUAL","primary_completion_date":"2029-05-10","primary_completion_date_type":"ESTIMATED","completion_date":"2030-03-25","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["AZN"]}